NEW YORK – Shimadzu and Diagnostics Development Hub (DxD Hub), a national platform hosted by Singapore's Agency for Science, Technology, and Research (A*STAR), said Monday that they are collaborating to establish the Shimadzu-DxD Hub Diagnomics Centre (SDDC).
Financial terms of the partnership were not disclosed.
The center, based at Singapore's Biopolis, aims to accelerate the development of high-quality, cost-effective diagnostic products by integrating expertise from Shimadzu with product development platforms from DxD Hub. It will focus on infectious diseases, cancer, and metabolic disorders.
Diagnostic products to be developed by SDDC will include PCR kits for faster and more accurate disease detection, as well as tests using Shimadzu's MALDI mass spectrometry and Fourier Transform Infrared spectroscopy platforms.
"Today, the world is experiencing a global surge in infectious diseases with over 40 countries reporting outbreaks at levels 10 times higher than pre-pandemic rates," Prem Anand, managing director of Shimadzu Asia Pacific, said in a statement. "In response to this urgent challenge, we are proud to partner with DxD Hub to make new strides in delivering solutions to infectious disease diagnostics."
"Our collaboration with Shimadzu Corporation supports Singapore’s efforts to grow as a global hub for diagnostic innovation," added DxD Hub CEO Weng Ruifen. "By contributing our productization expertise and working closely with industry partners, we help commercialize high-value intellectual property and translate scientific discoveries into practical healthcare solutions."